Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.9B
79M shares
52-week range
$22.10 – $45.14
76% from low
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Exchange
NASDAQ
CS
P/S (TTM)
27453
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
www.celldex.comNo one on the platform currently holds CLDX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 118,488 | $3.2M |
| Execution date | Ratio |
|---|---|
| 2019-02-11 | 1-for-15reverse |
| 2008-03-07 | 1-for-12reverse |
No one on the platform has traded CLDX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | -78.6% | -27.4% | ||||
| Profit Margin % | -17253.3% | -5567.7% | -3427.7% | |||
| Free Cash Flow Margin % | -14243.9% | -4783.8% | -2910.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2M | -37.5% | $-4.16 | $-4.22–$-4.02 | — | 8 |
| 2027 | $10M | +478.7% | $-4.21 | $-4.57–$-3.63 | — | 8 |
| 2028 | $118M | +1099.1% | $-3.45 | $-5.11–$-1.28 | — | 9 |
| 2029 | $478M | +305.9% | $-0.45 | $-1.01–$-0.04 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $-1.06 | $-0.94 | +11.3% |
| 2026-05-07 | $-1.15 | $-1.18 | -2.9% |
| 2026-02-25 | $-1.00 | $-1.22 | -22.0% |
| 2025-11-10 | $-0.88 | $-1.01 | -14.8% |
| 2025-08-07 | $-0.86 | $-0.85 | +1.2% |
| 2025-05-08 | $-0.75 | $-0.81 | -8.0% |
| 2025-02-27 | $-0.73 | $-0.71 | +2.7% |
| 2024-11-06 | $-0.69 |
| $-0.64 |
| +7.2% |
| $2.3B |
| — |
| JANXJanux Therapeutics, Inc. | $17.31 | +1.23% | $1.1B | — |
| NUVBNuvation Bio Inc. | $5.94 | -2.14% | $2.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$CLDX Goldman Warns Top Clients Of Unprecedented Split Within Momentum Trade - "Momentum leadership is changing" and "we expect this prolonged selloff in the AI complex to have lasting impact in the makeup of momentum and as this trend continues, momentum will start decoupling from AI." - towards Biotechs?!!
View on StockTwits ↗
$CLDX Someone wanted this for less and acted in a big way when the price was depressed, buying a ton of calls (and likely selling calls too)--Bull Call Spread. Nice bump today. Things could happen any day now as we are in Mid-Sept.
View on StockTwits ↗$CLDX Large bullish options flow included Nov 2026 45/65 bull call spreads (multi-million dollar debit), signaling institutional confidence. Phase 3 barzolvolimab CSU topline data (EMBARQ-CSU) expected Sept/Oct 2026 after early full enrollment of 1,939 patients; BLA planned for 2027. Positive momentum builds from Sept 10 Cantor Healthcare Conference presentation and transcript highlighting mast cell targeting pipeline and commercial prep. Morgan Stanley maintained Overweight with $50 PT (recent raise); consensus Moderate Buy/Strong Buy with ~$56-59 avg target.
View on StockTwits ↗$CLDX Any week now as we go into mid-late sept then into oct.
View on StockTwits ↗
$CLDX Morgan Stanley raised their target to $50 today
View on StockTwits ↗$CLDX Good positivity on the Cantor call this morning--big potential here! Data coming soon.
View on StockTwits ↗
🟢 $CLDX 45C Oct 16 💰 $118,300 premium 💵 $6.5/contract 📊 2.8x Vol/OI 📍 Spot $39.02 💰 Large premium 🌊 Dark Flow | Options Flow
View on StockTwits ↗
Wall St is expecting -1.02 EPS for $CLDX Q3 [Reporting 11/11 AMC] http://www.estimize.com/intro/cldx?chart=historical&metric_name=eps&utm_c
View on StockTwits ↗
@Timefortendies77 How is $CLDX working out for you? Lol. Like I had said we mught both play biotechs but we are not the same.
View on StockTwits ↗
$CLDX strolling through the minefield these next couple months, 10 years since a P3 readout. Curious to know how many longs from then are still long now. Helluva ride back hope the data impresses the market this time 🤞🏼
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.